drugset
drugset / Trial / NCT02897999

Single and Multiple Dose Evaluation of QBKPN SSI In Healthy Volunteers

NCT02897999 ↗

Phase 1 Withdrawn Qu Biologics Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this dose-escalation study is to assess the safety and pharmacodynamics of single and multiple doses of QBKPN SSI, administered subcutaneously to healthy adult volunteers

Timeline

Start
2016-09
Primary completion
2017-02
Completion
2017-02

Drugs

EvaluationDrugModalityDoseRoute
Subject QBKPN Other / unclassified 0.05 ml Subcutaneous
Subject QBKPN Other / unclassified 0.1 ml Subcutaneous
Subject QBKPN Other / unclassified 0.2 ml Subcutaneous
Subject QBKPN Other / unclassified 0.4 ml Subcutaneous
Subject QBKPN Other / unclassified 0.8 ml Subcutaneous
Subject QBKPN Other / unclassified 1.2 ml Subcutaneous

Indications

No indication recorded.